Related Experiment Video
Updated: Jul 13, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Arachidonic acid can significantly prevent early insulin resistance induced by a high-fat diet
Mianyun Wu1, Ximing Wang, Qiuhong Duan
1Biochemistry Department, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Aim:
To investigate whole-body metabolic disorder and hepatic glucose output (HGO) disturbance in rats with insulin resistance induced by a short-term high-fat diet, and the effect of arachidonic acid (AA).
Methods:
Twenty-four normal male Wistar rats (230-250 g) were randomly divided into 3 groups according to their weight and fed for 12 weeks: control group, n = 8, fed with standard chow diet; high-fat (HF) group, n = 8, fed with a high-fat diet; HF+AA group, n = 8, fed with a high-fat diet and administered orally 3 mg x kg(-1) x day(-1)AA.
Results:
Early insulin resistance was successfully induced in HF-fed rats with hyperinsulinemia (p < 0.05), higher plasma triglyceride (TG) (p < 0.05), higher fasting liver glycogen content (p < 0.01) and higher glucose-insulin index (p < 0.01) during an oral glucose tolerance test (OGTT). The AA treatment significantly decreased the glucose-insulin index (p < 0.01), blood TG (p < 0.05) and glycogen content (p < 0.05) in liver. Both activity of phosphoenolpyruvate carboxykinase (PEPCK) (p < 0.05) and mRNA levels of PEPCK (p < 0.05) and glucose-6-phosphatase (G-6-Pase) (p < 0.01) in liver were also observed to be significantly decreased. But there were significant differences in the glucose-insulin index (p < 0.01) during OGTT, and glycogen content (p < 0.01) between the HF+AA and control groups.
Conclusion:
AA can significantly prevent whole-body insulin resistance induced by a high-fat diet, as well as accompanied HGO disturbance in the overnight fasting state, but not thoroughly.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Insulin: The Receptor and Signaling Pathways
Type II Diabetes II: Pathophysiology
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Atherosclerosis III: Management
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

